These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 24342522)
1. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522 [TBL] [Abstract][Full Text] [Related]
2. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT; JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235 [TBL] [Abstract][Full Text] [Related]
3. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. Lantinga MA; D'Agnolo HM; Casteleijn NF; de Fijter JW; Meijer E; Messchendorp AL; Peters DJ; Salih M; Spithoven EM; Soonawala D; Visser FW; Wetzels JF; Zietse R; Drenth JP; Gansevoort RT; Drug Saf; 2017 Feb; 40(2):153-167. PubMed ID: 27995519 [TBL] [Abstract][Full Text] [Related]
4. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108 [TBL] [Abstract][Full Text] [Related]
5. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related]
6. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease. Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E; BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514 [TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]
8. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443 [TBL] [Abstract][Full Text] [Related]
10. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370 [TBL] [Abstract][Full Text] [Related]
11. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE; Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625 [TBL] [Abstract][Full Text] [Related]
12. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial. Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092 [TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041 [TBL] [Abstract][Full Text] [Related]
15. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE; Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517 [TBL] [Abstract][Full Text] [Related]
16. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G; PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521 [TBL] [Abstract][Full Text] [Related]
17. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial. Bais T; Meijer E; Kramers BJ; Vart P; Vervloet M; Salih M; Bammens B; Demoulin N; Todorova P; Müller RU; Halbritter J; Paliege A; Gall EC; Knebelmann B; Torra R; Ong ACM; Karet Frankl FE; Gansevoort RT Trials; 2024 Feb; 25(1):120. PubMed ID: 38355627 [TBL] [Abstract][Full Text] [Related]
18. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O; Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521 [TBL] [Abstract][Full Text] [Related]
19. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978 [TBL] [Abstract][Full Text] [Related]
20. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]